Gaskins Tammi L 4

What Happened

• Tammi L. Gaskins, Chief Commercial Officer of Ironwood Pharmaceuticals (IRWD), received an award of 136,612 restricted stock units (RSUs) on 2026-03-10. The reported acquisition price is $0.00, indicating these are performance/retention RSUs rather than an open-market purchase. No immediate cash changed hands; value is realized only as units vest and convert to shares.

Key Details

• Transaction date: 2026-03-10; Form 4 filed 2026-03-12 (timely filing).
• Transaction type/code: Award/Grant (A).
• Shares granted: 136,612 RSUs; reported acquisition price: $0.00.
• Shares owned after transaction: not disclosed in this filing.
• Footnote: Award vests as to 25% of the Class A common stock on each approximate anniversary of the grant (i.e., roughly a four-year vesting schedule).
• No 10b5-1 plan, tax withholding, or sale information reported in this filing.

Context

• These RSUs are a long-term compensation award and do not represent an immediate purchase or sale of shares. They will convert to actual shares (and potentially create dilution) only as they vest according to the stated schedule. For investors, grants signal how a company compensates executives but do not necessarily indicate immediate insider conviction through buying or selling.